Browsing Tag
BCR::ABL1 inhibitor
1 post
Enliven Therapeutics’ ELVN-001 shows strong Phase 1 results in CML, with Phase 3 plans in 2026
ELVN-001 from Enliven Therapeutics shows 47% MMR in CML trial; see what this means for the stock outlook and future Phase 3 plans. Read more.